Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.

Signal transduction and targeted therapy·2026
Same author

Microbiota, systemic immunity, and extracellular vesicles in stroke: peripheral nodes as therapeutic leverage points.

Journal of neuroinflammation·2026
Same author

Assessment of occult blood and bacterial contamination on protective lead garments in a tertiary hospital.

American journal of infection control·2026
Same author

Epigenetically regulated pancreatic GABA-somatostatin signaling underlies gestational diabetes-induced glucose intolerance in offspring.

Science translational medicine·2026
Same author

Mortality trends and disparities associated with aortic aneurysm and aortic dissection in the United States from 1999 to 2023: a CDC WONDER database analysis.

BMC cardiovascular disorders·2026
Same author

Aggregation of gene regulatory information and knowledge on FAIR principles enables discovery of pathogenic gene regulatory variants.

Bioinformatics (Oxford, England)·2026
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
Same journal

PACAP and Maxadilan (PAC1 Agonist) Influence Plaque Progression, Migratory Ability, and Mitochondrial Morphology and Dynamics in Vascular Smooth Muscle Cells.

Cells·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation.

Jiao Lu1, Christopher Ward2, Sichong Qian1

  • 1Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, One Baylor Plaza, R616 ABBR Bldg., Houston, TX 77030, USA.

Cells
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

Histone deacetylase 3 (HDAC3) is crucial for normal heart electrical activity. Its depletion or inhibition by drugs causes QT prolongation and other EKG abnormalities, revealing mechanisms of drug-induced cardiotoxicity.

Keywords:
QT prolongationcancercardiac electrical abnormalitieselectrocardiogramhistone deacetylase 3histone deacetylase inhibitorspotassium channelstoxicity

More Related Videos

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Related Experiment Videos

Last Updated: May 28, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylase (HDAC) inhibitors show therapeutic potential but can cause cardiac side effects, including QT interval prolongation.
  • The precise mechanisms behind HDAC inhibitor-associated cardiotoxicity are not fully understood.

Purpose of the Study:

  • To investigate the role of HDAC3 in cardiac electrophysiology.
  • To elucidate the molecular mechanisms underlying HDAC inhibitor-induced cardiotoxicity.

Main Methods:

  • Investigated the effects of postnatal and adult-onset inducible cardiac-specific HDAC3 depletion in mice.
  • Assessed electrocardiogram (EKG) abnormalities and ion channel gene expression.
  • Administered HDAC inhibitors (romidepsin, mocetinostat) to mice and evaluated cardiac effects.

Main Results:

  • Cardiac HDAC3 depletion in mice led to QT interval prolongation and other EKG abnormalities (T-wave changes).
  • Loss of HDAC3 deacetylase activity alone was sufficient to cause QT prolongation.
  • HDAC3 disruption and HDAC inhibitor treatment downregulated key potassium channel genes (e.g., Kcnh2, Kcne1, Kcnip2).

Conclusions:

  • HDAC3 enzymatic activity is a critical regulator of cardiac repolarization.
  • Findings provide mechanistic insights into HDAC inhibitor-associated cardiotoxicity, particularly concerning ion channel function.